Biotech Stock Report 10.03.09
Tuesday, 10 March, 2009
The pharmaceuticals and biotechnology sector was mostly flat recording a small 0.11% increase for the day.
Market heavyweight CSL (ASX:CSL) was stable, up 28c to $35.44.
Living Cell Technologies (ASX:LCT) recorded spectacular increase of 31%, to close at 10.5c but is still trading near its 52 week low of 8c.
Prana Biotechnology (ASX:PBT) and IDT Australia (ASX:IDT) were among the day's weaker performers in the pharmaceuticals and biotechnology sector, down 8% and 6% respectively with Bionomics Limited (ASX:BNO) not far behind, 5% down to 20c.
Chemgenex Pharmaceuticals (ASX:CXS) recorded a solid 6% rise to 34c, but is still well down on its 52 week high of $1.25. Novogen and Progen also moved up over 3%.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
